Xolair’s Price Discount For NICE Is Ominous Sign For Older Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.
You may also be interested in...
German State Court Ruling Against Novartis Confirms Legality of HTA For Older Products
A State Social Court of Berlin-Brandenburg ruling against Novartis means that Germany's reimbursement bodies can move forward with the benefit assessment of older pharmaceutical products.
U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts
In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.
Germany's G-BA Sets Out Financial-Based Criteria For Assessing Drugs Already On The Market
Germany's senior reimbursement body, the G-BA, has set out criteria – based on the financial success of products – to evaluate drugs already on the market.